Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study.
Verena Angerer, Yasmin Schmid, Florian Franz, Heike Gnann, Jan Manuel Speer, Anke Gnann, Stephan Helmecke, Armin Buchwald, Simon D Brandt, Torsten Passie, Matthias E Liechti, Volker Auwärter
Drug testing and analysis September 1, 2024 Peer reviewed DOI: 10.1002/dta.3622 via PubMed
Summary
MDAI, a new psychoactive substance, was tested in six healthy volunteers at a dose of 3.0 mg/kg. It produced subjective effects similar to those of 125 mg MDMA and increased blood pressure without affecting heart rate or body temperature. MDAI also elevated cortisol and prolactin levels and was detectable in serum for at least four days and in urine for at least six days. Further research is needed to explore its potential medicinal properties.
Study at a glance
| Sample size | 6 |
|---|---|
| Population | healthy volunteers |
| Key finding | MDAI produced subjective effects comparable to those of 125 mg MDMA while increasing blood pressure but not heart rate or body temperature. |
Abstract
The acute psychoactive, autonomic, and endocrine effects of the new psychoactive substance (NPS) 5,6-methylenedioxy-2-aminoindane (MDAI; 3.0 mg/kg, range 180-228 mg) were investigated in six healthy volunteers (four males, two females) in a non-blinded fashion without placebo. Subjective, cardiovascular, and endocrine responses were compared with two different doses of 3,4-methylenedioxymethamphetamine (MDMA) (75 mg and 125 mg) described in previously published placebo-controlled studies, which used identical outcome measures including Visual Analogue Scales (VAS), the Adjective Mood Rating Scale (AMRS), and the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale. MDAI was well tolerated and produced subjective effects comparable with those of 125 mg MDMA. MDAI increased blood pressure similar to 125 mg MDMA but did not increase heart rate or body temperature. MDAI increased cortisol and prolactin levels and could be detected in serum about 20 min post ingestion and remained detectable at least for 4 days. In urine, MDAI was detectable over a period of at least 6 days. Further clinical investigations are warranted to assess whether MDAI could serve as drug with medicinal properties.